Search results for "Toni"

showing 10 items of 8001 documents

Measuring and modeling real-time responses to music: the dynamics of tonality induction.

2003

We examined a variety of real-time responses evoked by a single piece of music, the organ Duetto BWV 805 by J S Bach. The primary data came from a concurrent probe-tone method in which the probe-tone is sounded continuously with the music. Listeners judged how well the probe tone fit with the music at each point in time. The process was repeated for all probe tones of the chromatic scale. A self-organizing map (SOM) [Kohonen 1997 Self-organizing Maps (Berlin: Springer)] was used to represent the developing and changing sense of key reflected in these judgments. The SOM was trained on the probe-tone profiles for 24 major and minor keys (Krumhansl and Kessler 1982 Psychological Review89 334–…

AdultMaleAcousticsSpeech recognitionExperimental and Cognitive Psychology050105 experimental psychology060404 musicPitch classTone (musical instrument)Artificial IntelligencePsychophysicsHumans0501 psychology and cognitive sciencesChromatic scaleTonalityPitch PerceptionMajor and minorSupertonic05 social sciences06 humanities and the artsScale (music)Sensory SystemsOphthalmologyDynamics (music)Auditory PerceptionFemalePsychology0604 artsMusicPerception
researchProduct

Pharmacokinetic Interactions of Clozapine With Selective Serotonin Reuptake Inhibitors

1998

Pharmacokinetic interactions of clozapine and its metabolites N-desmethylclozapine and clozapine N-oxide with the selective serotonin reuptake inhibitors (SSRIs) fluvoxamine and paroxetine were investigated in a prospective study in schizophrenic patients under steady-state conditions. Thirty patients were treated with clozapine at a target dose of 2.5 to 3.0 mg/kg of body weight. After gradual dose escalation, serum concentrations of clozapine and two metabolites were determined twice at 7-day intervals after steady-state conditions had been reached. Then, fluvoxamine (50 mg/day) or paroxetine (20 mg/day) was added in 16 and 14 patients, respectively. Serum concentrations of clozapine and …

AdultMaleAdolescentFluvoxaminePharmacologyPharmacokineticsmedicineHumansDrug InteractionsPharmacology (medical)Prospective StudiesProspective cohort studyClozapineClozapinebusiness.industrySmokingMiddle AgedDrug interactionParoxetineParoxetinePsychiatry and Mental healthFluvoxamineSchizophreniaFemaleSerotoninbusinessReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine.

1998

A six-week double-blind placebo-controlled trial of fluvoxamine was undertaken in 46 patients suffering from panic disorder with or without agoraphobia diagnosed by DSM-III-R guidelines. Average daily dosage of fluvoxamine was 160 mg, with a highest permitted dose of 300 mg/day. Weekly evaluation included a diary in which the number, severity, and duration of full-blown and limited panic attacks and the duration and severity of anticipating fear, CAS, GAS, CGI, HAM-D, adverse effects and the number of capsules not taken were noted. Fluvoxamine was not significantly superior to placebo with regard to the main outcome criterion, i.e., the reduction in the number of panic attacks, but it was s…

AdultMaleAdolescentFluvoxaminePlacebolaw.inventionRandomized controlled trialDouble-Blind Methodlawmental disordersmedicineHumansPharmacology (medical)Adverse effectAgedPsychiatric Status Rating ScalesPanic disorderPanicGeneral MedicineMiddle Agedmedicine.diseasehumanitiesPsychiatry and Mental healthAnti-Anxiety AgentsFluvoxamineAnesthesiaPanic DisorderFemalemedicine.symptomDrug MonitoringPsychologyAnxiety disorderSelective Serotonin Reuptake Inhibitorsmedicine.drugAgoraphobiaPharmacopsychiatry
researchProduct

Addition of Low-Dose Fluvoxamine to Low-Dose Clozapine Monotherapy in Schizophrenia: Drug Monitoring and Tolerability Data from a Prospective Clinica…

1999

Combining fluvoxamine and clozapine may be a strategy to improve therapeutic effects on negative symptoms in schizophrenic patients. Fluvoxamine, however, markedly inhibits the metabolism of clozapine, and hazardous side effects may result. This study prospectively investigated the safety and tolerability of an add-on therapy with fluvoxamine to a clozapine monotherapy in schizophrenic patients. Sixteen schizophrenic patients received 50 mg fluvoxamine as a comedication after having reached steady-state conditions under clozapine monotherapy. Patients were monitored for subjective adverse events, laboratory parameters, EEG and ECG recordings, orthostatic hypotension and their psychopatholog…

AdultMaleAdolescentMatched-Pair AnalysisFluvoxamineDrug Administration ScheduleOrthostatic vital signsmedicineHumansDrug InteractionsPharmacology (medical)Prospective StudiesAdverse effectClozapineClozapineTherapeutic effectGeneral MedicineMiddle AgedDrug interactionPsychiatry and Mental healthTreatment OutcomeTolerabilityFluvoxamineAnesthesiaSchizophreniaAntidepressive Agents Second-GenerationDrug Therapy CombinationFemaleDrug MonitoringPsychologyReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine

2011

The objective of this study was to evaluate patients’ satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1–3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting <3 months. At study end patients assigned preference to one of the treatments using a questionnaire with a score from 0 to 5 (primary endpoint). Secondary endpoints w…

AdultMaleAdolescentOriginalMigraine with AuraPopulationAlmotriptanCarbazolesClinical NeurologyMigraine; almotriptan; FrovatriptanYoung Adultalmotriptan; frovatriptan; migraine; patient preferenceDouble-Blind MethodAlmotriptanmedicineHumansMigraine Frovatriptan Almotriptan Patient preferencePatient preferenceeducationMigraineAgededucation.field_of_studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyRizatriptanTryptaminesMigraine with auraSerotonin Receptor AgonistsalmotriptanTreatment OutcomeAnesthesiology and Pain MedicineItalyMigraineTolerabilityAnesthesiaAcute DiseaseFemaleSettore MED/26 - NeurologiaNeurology (clinical)medicine.symptombusinessFrovatriptanFrovatriptanmedicine.drug
researchProduct

Internalized myofiber capillaries: Observations on their origin and clinical features

1989

Internalized capillaries limited to type 1 muscle fibers were noted in seven patients. They occurred in each case in association with a similar admixture of neurogenic and myopathic features that included atrophic and hypertrophic fibers, internal nuclei, fiber splitting, and endomyseal and perimyseal fibrosis. Internalized capillaries in enlarged type 1 fibers arose from fiber splits on step section study of four patients. They occurred in the gastrocnemius, quadriceps, and soleus muscles from patients with a variety of disorders that included Becker dystrophy, diabetes mellitus and strenuous leg activities, Achilles tendon rupture, and myotonic dystrophy. Exercise-induced myalgias were no…

AdultMaleAdolescentPhysiologyMyotonic dystrophyMuscle hypertrophyCellular and Molecular NeuroscienceMuscular DiseasesTendon InjuriesFibrosisPhysiology (medical)HumansMyotonic DystrophyMedicineMyocyteProspective StudiesMuscular dystrophyRupturebusiness.industryMusclesAnatomyMiddle Agedmedicine.diseaseMyotoniaCapillariesDiabetes Mellitus Type 1Neurology (clinical)Achilles tendon rupturemedicine.symptombusinessPolyneuropathyMuscle &amp; Nerve
researchProduct

Processing of auditory stimuli during tonic and phasic periods of REM sleep as revealed by event-related brain potentials

1996

The brain has been reported to be more preoccupied with dreams during phasic than during tonic REM sleep. Whether these periods also differ in terms of the processing of external stimuli was examined. Event-related brain potentials (ERPs) to a frequent standard tone of 1000 Hz (P = 97%) and infrequent deviant tones of 1100 and 2000 Hz (P = 1.5% for each) were recorded (n = 13) during wakefulness and nocturnal sleep. An ERP wave (called REM-P3) resembling a waking P3 wave was larger for the 2000 Hz deviant during tonic than during phasic REM sleep. Also the P210 wave was larger during tonic than during phasic REM sleep. A reliable mismatch negativity component appeared only in wakefulness. I…

AdultMaleAuditory perceptionmedicine.medical_specialtyCognitive NeuroscienceSleep REMMismatch negativityElectroencephalographyAudiologyNon-rapid eye movement sleepTonic (physiology)Behavioral NeuroscienceEvent-related potentialmental disordersmedicineHumansWakefulnessEvoked Potentialsmedicine.diagnostic_testmusculoskeletal neural and ocular physiologyBrainElectroencephalographyGeneral MedicineAuditory PerceptionAuditory stimuliFemaleWakefulnessPsychologyNeurosciencepsychological phenomena and processesJournal of Sleep Research
researchProduct

Procalcitonin levels in candidemia versus bacteremia: a systematic review

2019

Background Procalcitonin (PCT) is a biomarker used to assess systemic inflammation, infection, and sepsis and to optimize antimicrobial therapies. Its role in the in the differential diagnosis between candidemia and bacteremia is unclear. The aim of this systematic review was to summarize the current evidence about PCT values for differentiating candidemia from bacteremia. Methods PubMed and EMBASE were searched for studies reporting data on the diagnostic performance of serum PCT levels in intensive care unit (ICU) or non-ICU adult patients with candidemia, in comparison to patients with bacteremia. Results We included 16 studies for a total of 45.079 patients and 785 cases of candidemia. …

AdultMaleCalcitoninmedicine.medical_specialtyLetterBacteremiaCritical Care and Intensive Care MedicineProcalcitoninlaw.inventionSepsis03 medical and health sciences0302 clinical medicineBiomarker; Candida; Candidemia; Fungal; Fungi; PCT; Procalcitonin; SepsislawSecondary analysisSepsisparasitic diseasesmedicineHumansIntensive care medicineCandidaAdult patientsbusiness.industryResearchlcsh:Medical emergencies. Critical care. Intensive care. First aidFungiCandidemia030208 emergency & critical care medicinelcsh:RC86-88.9Biomarkermedicine.diseasebacterial infections and mycosesIntensive care unitFungalBacteremiaBiomarker (medicine)FemaleDifferential diagnosisbusinessPCTProcalcitoninhormones hormone substitutes and hormone antagonistsBiomarkersCritical Care
researchProduct

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine : a phase 2 randomised, placebo-control…

2012

Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. We aimed to assess the efficacy and safety of oral lasmiditan for the acute treatment of migraine.In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg lasmiditan, or placebo. Study drug and placebo were sup…

AdultMaleDrug-Related Side Effects and Adverse ReactionsPyridinesPopulationMedizinAdministration OralKaplan-Meier EstimatePlacebolaw.inventionYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodPiperidinesRandomized controlled triallawHumansMedicineAdverse effecteducationAgededucation.field_of_studyDose-Response Relationship Drugbusiness.industryMiddle AgedDose-ranging studymedicine.diseaseLasmiditanSerotonin Receptor Agonists3. Good healthTreatment OutcomechemistryTolerabilityMigraine030220 oncology & carcinogenesisAnesthesiaBenzamidesFemaleNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients With Acute-on-Chronic Liver Failure

2012

BACKGROUND & AIMS: Fractionated plasma separation and adsorption (FPSA) is an extracorporeal procedure that supports liver function by removing endogenous toxins that cause complications from acute-on-chronic liver failure (AOCLF). We performed a randomized trial to investigate survival of patients with AOCLF treated with FPSA. METHODS: Patients with AOCLF were randomly assigned to groups given a combination of FPSA and standard medical therapy (SMT) (FPSA group, n = 77) or only SMT (SMT group, n = 68). The Prometheus liver support system was used to provide 8 to 11 rounds of FPSA (minimum of 4 hours each) for 3 weeks. Primary end points were survival probabilities at days 28 and 90, irresp…

AdultMaleExtracorporeal Circulationmedicine.medical_specialtyTime FactorsCirrhosismedicine.medical_treatmentMedizinKaplan-Meier EstimateLiver transplantationRisk AssessmentGastroenterologyEnd Stage Liver DiseaseLIVER DISEASELiver diseaseSpontaneous bacterial peritonitisHepatorenal syndromeRisk FactorsInternal medicinemedicineHumansProspective StudiesDialysisProportional Hazards ModelsHepatologybusiness.industryMORTALITYGastroenterologyBilirubinTREATMENTLiver Failure AcuteMiddle Agedmedicine.diseaseEXTRACORPOREAL LIVER SUPPORTSurgeryEuropeTreatment OutcomeFemaleSorption DetoxificationSOFA scoreLiver functionORGAN FAILUREbusinessBiomarkers
researchProduct